Sernova Corp. (TSE:SVA - Get Free Report)'s stock price traded down 5.8% during trading on Wednesday . The company traded as low as C$0.24 and last traded at C$0.25. 170,306 shares changed hands during mid-day trading, an increase of 1% from the average session volume of 169,294 shares. The stock had previously closed at C$0.26.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on SVA shares. Ventum Cap Mkts upgraded shares of Sernova to a "strong-buy" rating in a research report on Thursday, September 12th. Ventum Financial cut their target price on shares of Sernova from C$3.00 to C$2.50 and set a "buy" rating for the company in a research report on Friday, September 13th. Finally, Leede Financial cut their target price on shares of Sernova from C$3.00 to C$1.50 and set a "speculative buy" rating for the company in a research report on Friday, September 13th.
Read Our Latest Stock Report on Sernova
Sernova Trading Down 2.0 %
The firm's 50-day simple moving average is C$0.26 and its 200-day simple moving average is C$0.30. The company has a quick ratio of 18.11, a current ratio of 0.32 and a debt-to-equity ratio of 16.55. The firm has a market capitalization of C$78.08 million, a PE ratio of -1.92 and a beta of 1.35.
Sernova (TSE:SVA - Get Free Report) last posted its earnings results on Monday, September 16th. The company reported C($0.02) earnings per share for the quarter, topping analysts' consensus estimates of C($0.03) by C$0.01. Equities analysts expect that Sernova Corp. will post -0.08 earnings per share for the current year.
Insider Transactions at Sernova
In other news, Director Steven Sangha sold 930,000 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of C$0.24, for a total transaction of C$223,200.00. Over the last ninety days, insiders bought 142,600 shares of company stock worth $33,776. Company insiders own 12.13% of the company's stock.
About Sernova
(
Get Free Report)
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.
Read More
Before you consider Sernova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sernova wasn't on the list.
While Sernova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
